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Abstract 
Oncogenic events combined with a favourable environment are the two main factors in the 
oncological process. The tumour microenvironment is composed of a complex, interconnected 
network of protagonists, including soluble factors suh as cytokines, extracellular matrix 
components, interacting with fibroblasts, endothelial cells, immune cells and various specific 
cell types depending on the location of the cancer cells (e.g. pulmonary epithelium, osteoblasts). 
This diversity defines specific “niches” (e.g. vascular, immune, bone niches) involved in 
tumour growth and the metastatic process. These actors communicate together by direct 
intercellular communications and/or in an autocrine/paracrine/endocrine manner involving 
cytokines and growth factors. Among these glycoproteins, RANKL and its receptor RANK, 
members of the TNF and TNFR superfamilies, have stimulated the interest of the scientific 
community. RANK is frequently expressed by cancer cells in contrast to RANKL which is 
frequently detected in the tumour microenvironment and together they participate in every step 
in cancer development. Their activities are markedly regulated by OPG (a soluble decoy 
receptor) and its ligands, and by LGR4, a membrane receptor able to bind RANKL. The aim of 
the present review is to provide an overview of the functional implication of the 
RANK/RANKL system in cancer development, and to underline the most recent clinical 
studies. 
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1. Introduction 
 In a physiological context, a healthy tissue microenvironment provides an adapted 
three-dimensional microarchitecture with essential intercellular signalling, thus ensuring 
appropriate function. This tissue homeostasis acts as a barrier to tumour development by 
inhibiting excessive cell growth and/or migration. Indeed, this fragile equilibrium can be 
destabilised by any alterations to cell communications, or interaction between cells and 
extracellular matrix components and consequently can become a fertile environment for cancer 
cells, promoting their malignant transformation and their proliferation [1]. The conjunction 
between one or more oncogenic events and this fertile environment can lead to the development 
of a tumour mass, which is frequently linked to the tumour cells escaping from the immune 
system [2]. In fact, this description reflects the “seed and soil” theory proposed by Stephan 
Paget in 1889 to explain preferential metastatic sites depending on tumour subtype [3].  
 This “soil” or tumour microenvironment is a very complex and dynamic organisation, 
defined by three main “niches” depending on their functional implication: i) an immune niche 
involved in local immune tolerance, ii) a vascular niche associated with tumour cell 
extravasation/migration, and iii) a metastatic niche (e.g. bone, lung, liver) hosting the 
metastastic tumour cells [4,5]. The notion of tumour niche was initially described for 
haematopoietic stem cells, for which the bone microenvironment is composed of complex 
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signalling pathways that carefully regulate stem cell renewal, differentiation and quiescence 
[6]. The concept of tumour niche was then extended to bone metastases, such as breast or 
prostate cancers [7]. Lu et al. described a model of bone metastasis dormancy in breast cancer 
where VCAM-1, aberrantly expressed, promoted the transition from indolent micrometastasis 
to proliferating tumour by recruiting and activating in situ osteoclastic cells [8]. More recently, 
Wang et al. analysed the distribution of human prostate cancer cell lines colonising mouse 
bones after intracardiac injection of tumour cells and demonstrated that homing of prostate 
cancer cells was associated with the presence of activated osteoblast lineage cells [9]. These 
two recent manuscripts are perfect examples of the involvement of the tumour environment in 
the biology of bone metastases. 
The tumour microenvironment thus provides all the factors necessary for cancer cell 
survival, dormancy, proliferation or/and migration [10] and very often, tumour cells divert this 
environment in their favour [8]. Indeed, this specific microenvironment has recently been 
involved in the maintenance of cancer cell dormancy [12-14] and may also play a part in drug 
resistance mechanisms by controlling the balance between cell proliferation and cell death, or 
by secreting soluble factors that dysregulate the cell cycle checkpoints, the cell death associated 
signalling pathways, or drug efflux [15,16].  
Cell communications in physiological and pathological conditions are promoted by 
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physical contacts involving adhesion molecules and channels, but also by a very high number 
of soluble mediators called cytokines and growth factors which appear to be the key 
protagonists in the dialogue established between cancer cells and their microenvironment [16]. 
These polypeptidic mediators perform their activities in an autocrine, paracrine or juxtacrine 
manner leading to inflammatory foci and the establishment of a vicious cycle between cancer 
cells and their local niches [17-19]. These proteins also have endocrine activities and contribute 
in this way to both the formation of a chemoattractant gradient and the metastatic process. 
 Considerable diversity in the cytokines and growth factors playing a role in cancer 
development has been identified in the last four decades. Some of them can be considered to be 
biological markers for aggressiveness, or to be prognostic factors, while others are also 
regarded as therapeutic targets. Among cytokine families, in the last 15 years, the biology of 
Receptor Activator Nuclear Factor kappa B Ligand (RANKL) and its receptor RANK has been 
widely studied in cancer [20-23] and has been identified as a key therapeutic target in numerous 
cancer entities, as described below. The present review gives a synthesis of RANK/RANKL 
pathway involvement in the carcinogenesis process. Their direct or indirect activities in 
oncogenic events will be described, as will their recent therapeutic applications. 
2. RANKL/RANK system: discovery, molecular and functional characterization 
The superfamily of Tumor Necrosis Factor-α (TNFα) is composed of more than 40 members 
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and is associated with a similar number of membrane or soluble receptors. Receptor Activator 
of Nuclear factor Kappa B Ligand (RANKL) is one member of the TNF-α superfamily 
(TNFSF11) and binds to a membrane receptor named Receptor Activator of Nuclear factor 
Kappa B (RANK), a member of the TNF receptor superfamily (TNFRSF11A) [20-30]. The 
interactions between RANKL and RANK lead to specific intracellular signal transduction and 
are controlled by a decoy receptor called osteoprotegerin (OPG) (TNFRSF11B) [27] (Figure 1). 
 
2.1. RANKL 
RANKL has alternatively been called tumour necrosis factor-related activation-induced 
cytokine (TRANCE) [26], osteoprotegerin ligand (OPGL) [27] and osteoclastic differentiation 
factor (ODF) [30]. Although RANKL is the name commonly used, the official nomenclature of 
this cytokine is TNFSF11. RANKL is a homotrimeric type II membrane protein with no signal 
peptide and existing in three isoforms due to alternative splicing of the same gene [31]. Among 
these isoforms, the full-length RANKL is called RANKL1, RANKL2 is a shorter form of 
RANKL1 in which a part of the intra-cytoplasmic domain is missing, and RANKL 3 is a 
soluble form of RANKL, with the N-terminal part of the amino acids deleted [31]. A soluble 
RANKL can also result from the sheding of membrane-RANKL induced by various enzymes 
such as the metalloproteinase disintegrin TNF-α converting enzyme (TACE) [32] or 
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ADAM-10, MMP-7, MMP-14 [33,34]. RANKL is expressed by a wide variety of tissues such 
as the brain, skin, intestine, skeletal muscle, kidney, liver, lung, and mammary tissue, but is 
more highly expressed in bone tissue [35], lymphoid organs and the vascular system [36]. The 
control of bone remodelling is the predominant function of RANKL. Indeed, RANKL 
effectively regulates the bone resorption process by stimulating osteoclast differentiation and 
osteoclast survival [37,38]. Whether RANKL is expressed by osteoblasts, osteocytes, 
chondrocytes or stromal cells, osteocytes are its main source in adult bone [39,40]. The role of 
RANKL is not restricted to the bone tissue and RANKL also plays an important role in the 
immune system, increasing the ability of dendritic cells to stimulate both naive T-cell 
proliferation and the survival of RANK+ T cells [25,26,41]. In this context, Wong et al. 
demonstrated that RANKL is a specific survival factor for dendritic cells [27].  Overall, 
RANKL is one of the key factors at the crossroad between bones and immunity, a topic called 
“osteoimmunology” [42].   
2.2 RANK 
Receptor activator of nuclear factor kappa-B, also known as TRANCE receptor [43] and 
TNFRSF11A, is the signalling receptor for RANKL [25]. RANK belongs to the TNF 
superfamily receptors and is a type I transmembrane protein. This receptor has a large 
cytoplasmic domain at its C-terminal domain, a N-terminal extracellular domain with four 
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cystein-rich repeat motifs and two N-glycosylation sites [21]. Its last domain is involved in the 
interaction with RANKL and the induction of the receptor’s trimerisation [44,45]. RANK 
mRNAs have been detected in many tissues such as the thymus, mammary glands, liver, and 
prostate, but more significantly in bone [21,25]. By transducing the cell signalling initiated by 
RANKL, RANK plays a part in controlling bone remodelling and immunity [46,47]. Its 
functional activities have been clearly established by studying the phenotype of RANK 
knockout mice which exhibit severe osteopetrosis, with a lack of mature osteoclasts, and an 
absence of lymph node development with impairment in B and T cell maturation [48,49]. 
RANK is then the second key protagonist of “osteoimmunology” [50]. 
 
3. RANK/RANKL and cancer  
3.1. RANK expression identifies cancer cells as RANKL targets 
The expression of RANK/RANKL is not restricted to healthy tissues and numerous studies 
have demonstrated their expression in neoplastic tissues. This wide distribution strengthens the 
hypothesis of their key role in the oncogenic process (Table 1). Thus, a high percentage of 
carcinoma cells express RANK mRNA/protein at various levels [51,52]. Indeed, 89% of all the 
carcinomas assessed exhibit RANK positive immunostaining, and around 60 % of cases 
showed more than 50% of positive cancer cells. Interestingly, RANK expression in carcinoma 
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cells is a poor prognostic marker as demonstrated in breast cancer [86,87]. Similarly to prostate 
cancers, Pfitzner et al. demonstrated that higher RANK expression in the primary breast tumour 
was associated with higher sensitivity to chemotherapy, but also a higher risk of relapse and 
death despite this higher sensitivity [87]. RANK expression was also described as being 
predictive of poor prognosis in bone metastatic patients but not in patients with visceral 
metastases [88]. Similarly, sarcoma cells also express RANK (18-69% depending on the series) 
[79, 89, 90] and expression is correlated with clinical parameters. Trieb et al. described a 
reverse correlation between RANK expression and the overall survival of patients with 
osteosarcoma, but not with the response to chemotherapy [89]. These authors observed lower 
disease-free and overall survival rates in patients presenting RANK positive tumours. 
Bago-Horvath et al. revealed that RANKL expression was significantly more common in 
osteosarcoma of the lower extremity than in any other location and did not find any significant 
correlation between RANKL and disease-free or osteosarcoma-specific survival. However, 
they did report that RANK expression is a negative prognostic factor regarding disease-free 
survival, confirming the data obtained by Trieb et al. [90]. Interestingly, in 2012, Papanastasiou 
et al. identified a new isoform of RANK (named RANK-c) generated by alternative splicing 
and expressed in breast cancer samples. Its expression was reversely correlated with 
histological grade and RANK-c was able to inhibit cell motility and the migration of breast 
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cancer cells by interfering with RANK signalling [91].  
In several studies [87, 90], RANKL expression was not correlated with any clinical 
outcomes in either carcinoma or sarcoma. However, in one series of 40 patients, Lee et al. 
showed that RANKL expression was related to poor response to preoperative chemotherapy 
and a high RANKL level was associated with inferior survival [92]. Recently, Cathomas et al. 
described an interesting clinical case of an osteosarcoma patient treated with Sorafenib and 
Denosumab [93]. RANK and RANKL were expressed by the tumour cells and the authors 
observed complete metabolic remission for over 18 months strengthening the potential 
therapeutic value of blocking RANK/RANKL signalling in osteosarcoma [93]. Whereas 
RANK is expressed by various cancer cell types, its ligand can be produced either by tumour 
cells or by their environment (Table 1). Consequently, RANKL can then act in a paracrine or 
autocrine manner on cancer cells. The best example of such paracrine activity is given by the 
role of RANK/RANKL in the pathogenesis of giant cell tumours in bone. RANK is expressed 
by giant osteoclasts and the macrophagic component of the tumours, whereas RANKL is 
produced by stromal cells. Furthermore, exacerbated production of RANKL by stromal cells is 
directly associated with an increase in osteoclastogenesis and bone destruction [94]. This 
observation identifies the giant cell tumours in bone as very good candidates for the clinical use 
of Denosumab [95].  
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3.2. Direct RANK/RANKL signalling in cancer cells: the regulatory activities of OPG and 
LGR4 
RANK, like the other receptors in the TNF receptor superfamily, is characterised by the absence 
of tyrosine kinase activity and consequently requires adapter proteins named TNF-family 
receptor associated factors (TRAF) in order to transmit cell signalling. The intracellular domain 
of RANK has two TRAF binding sites able to interact with TRAF-2, -3, -5 and -6 [96,97], but 
only TRAF6 mutations led to an osteopetrotic phenotype similar to the phenotype of RANK 
knockout mice, thus underlining the predominant role of TRAF6 in RANK associated 
signalling among the TRAF family members [96-101]. Consecutively, TRAF6 leads to the 
activation of Src/PLCγ, PI3K/Akt/mTOR and MAPK (p38, JNK, ERK1/2) cascades which 
result in the translocation of transcriptional activators including NF-κB, Fos/Jun or MITF and 
subsequently to the transcription of numerous effector genes involved in bone resorption such 
as cathepsin K or TRAP, in cell adhesion and motility such as VCAM1 or ICAM1. This 
explains the various functional impacts that RANKL has on normal and cancer cells (Figure 1).  
The first identified regulator of RANKL activities was a soluble protein named 
osteoprotegerin (OPG) [102,103]. OPG is considered to be a ubiquitous protein with 
predominant expression in bone (osteoblasts, mesenchymal stem cells), immune cells 
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(dendritic cells, T and B cells) and vessels (endothelial and vascular smooth muscle cells) 
[21,104]. OPG acts as a decoy receptor for RANKL, and blocks the RANK-RANKL interaction 
and RANKL-induced signalling pathways with its N-terminal [11,89]. OPG and RANKL 
expression are both regulated by inflammatory cytokines released into the microenvironment of 
cancer cells, and RANKL activities will result from the level of expression and its the kinetics 
of both factors in this microenvironment [21,105]. OPG binds to soluble and membrane 
RANKL and strongly controls RANKL bioavailability at the cell membrane by facilitating its 
internalisation and reducing its half-life [106]. However, OPG possesses numerous other 
ligands which markedly regulate its expression and have an impact on RANKL availability 
(Figure 1) [104]. In this way, OPG binds to glycosaminoglycans and proteoglycans such as 
syndecan-1 through its heparin-binding domain with a strong influence on cancer cell 
development [104, 107]. The best illustration of the functional consequence of this interaction 
in cancer is given by myeloma cells which overexpress syndecan-1 [108]. OPG produced in the 
bone microenvironment is trapped, internalised and degraded by myeloma cells and the 
OPG/RANKL balance is then dysregulated in favour of RANKL. The OPG/RANKL imbalance 
leads to bone resorption, a phenomenon exacerbated by the RANKL production of the 
myeloma cells. By sequestering OPG, myeloma cells elaborate a microenvironment that 
facilitates their expansion. Similarly, OPG can be trapped by the proteoglycans and 
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glycosaminoglycans located in the extracellular matrix as shown in osteosarcoma [109]. In 
addition, OPG binds TRAIL (TNF Related Apoptosis Inducing Ligand), a key natural 
pro-apoptotic and “anti-cancer” factor [110]. By this way, OPG can thus act as an 
anti-apoptotic and a pro-proliferative factor for cancer cells by blocking TRAIL activity, as 
shown with prostate carcinoma for instance [111]. Complex VIII (factor VIII-von Willebrand 
factor) is also able to bind to OPG and increases the complexity of this system by regulating 
TRAIL-induced cancer cell death [112]. Finally, RANKL expressed by the tumour cells or/and 
their environment by exerting its action through RANK in an autocrine, endocrine or paracrine 
manner contributes to establishing the fertile soil needed for tumour cells to be maintained and 
proliferate. In this picture, OPG and its ligands are notably involved in the bioavailability and 
biological activities of RANKL. 
 Very recently, a new RANKL receptor named Leucine-rich repeat-containing 
G-protein-coupled receptor 4 (LRG4) characterised by seven transmembrane regions, has been 
identified [113]. In this work, Luo et al. revealed that RANKL binds to the extracellular domain 
of LGR4 and by this way negatively regulates osteoclastogenesis through activation of 
Gαq/GS3K-β signalling and repression of the NFATc1 pathway [113] (Figure 1). Moreover,  
Lgr4 is a transcriptional target of the canonical RANKL-NFATc1, which shows that LGR4 
signalling acts as the feedback loop controlling RANKL activities. Interestingly, a mutation in 
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LGR4 encoding gene has been related to an osteoporosis phenotype which can be explained by 
the new function of LGR4 as a RANKL receptor [114]. Although the involvement of the 
LRG4-RANKL axis in cancer has not yet been clearly determined, LGR4 nevertheless 
promotes the proliferation of various tumour cells, including breast, prostate, gastric and 
hepatic cancer [115]. This proliferation effect was linked to activation of the Wnt/β catenin 
signalling pathways. LRG4 appears to be a new regulator for prostate development and 
promotes tumorigenesis [116,117] and the LRG4-Stat3 molecular pathway may control 
osteosarcoma development [118].  
RANKL activities are modulated by the balance between RANKL and their various 
molecular regulators produced in the microenvironment of cancer cells. RANKL is involved in 
each stage of tumour development, from the initial oncogenesis process to the establishment of 
the distant metastases as described below (Figure 2). 
 
 
3.3. The RANK/RANKL axis is involved in the initial phases of tumour development 
Initially considered to be a pro-metastatic factor, our vision of RANKL changed when the 
factor was linked to mammary gland development [119]. RANKL deficiency leads to a defect 
in the formation of the lobo-alveolar structures required for lactation [120,121]. In addition, 
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RANKL is able to promote the survival and proliferation of epithelial cells simultaneously with 
the upregulated expression of RANK during mammary gland development [119-121]. 
Disturbance in this coordinated mechanism can lead to the formation of preneoplasias and 
subsequently to that of tumour foci, as revealed by Gonzalez-Suarez et al. [122]. These authors 
established a mouse mammary tumour virus – RANK transgenic mice overexpressing the 
protein in mammary glands – and reported a high incidence of pre-neoplasia foci (multifocal 
ductal hyperplasias, multifocal and focally extensive mammary intraepithelial neoplasias), as 
well as the development of adenocarcinoma lesions in these transgenic mice compared to the 
wild-type mice. Confirming the involvement of RANKL in the initial oncogenic process, 
administration of RANK-Fc decreased both mammary tumorigenesis and the development of 
lung metastases in MMTV-neu transgenic mice, a spontaneous mammary tumour model [122]. 
In a complementary work, this team demonstrated that the RANKL/RANK axis was pro-active 
in epithelial mesenchymal transition (EMT), promoted cell migration simultaneously with 
neo-vascularisation, and that their expression was significantly associated with metastatic 
tumours [103]. Overall, their data revealed that RANK/RANKL signalling promotes the initial 
stage in breast cancer development by inducing stemness and EMT in mammary epithelial 
cells. A similar process has been confirmed in head and neck squamous carcinoma [124], and in 
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endometrial cancer [125], and RANKL expression has been associated with the EMT and 
appears to be a new marker for EMT in prostate cancer cells [83]. 
 
3.4. RANK/RANKL system controls cell motility and consequently contributes to the 
metastastic process concomitantly with a pro-angiogenic function 
Jones et al. provided the first evidence of a chemoattractant activity for RANKL [95]. These 
authors demonstrated that RANKL produced by osteoblasts and bone marrow stromal cells 
attracts RANK-expressing cancer cells and induces their migration. This mechanism seems to 
be relatively universal and was observed in prostate cancer [95, 125, 126], breast cancer [95], 
colon cancer [58], melanoma [95], oral squamous carcinomas [127], lung cancer [128], 
hepatocarcinoma [129], endometrial cancer [130], osteosarcoma [131, 132], and renal cancer 
[133]. RANKL-induced migration is associated with specific signalling cascades, especially 
the activation of MAP Kinase pathways. The RANKL/RANK axis then regulates cancer cell 
migration and RANKL acts as a chemoattractive agent on cells that express one of their 
receptors.  
In addition to its direct effects on cancer cells, RANKL is notably able to modulate the 
tumour microenvironment, in particular the formation of new blood vessels. Blood vessels are 
used by cancer cells to deliver large quantities of nutriments and are their main means of 
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migrating so as to invade distant organs. RANK expression was detected in endothelial cells, 
and by interacting with this receptor, RANKL impacts the angiogenic process by both 
stimulating angiogenesis through an Src and phospholipase C-dependent mechanism [132,133], 
and increasing cell survival in a PI3k/Akt-dependent manner [134]. RANKL also induced the 
proliferation of endothelial cell precursors and the neoformation of vascular tubes [135]. This 
phenomenon is exacerbated by VEGF, which is frequently secreted by cancer cells and which 
upregulates the RANKL response of endothelial cells by an upregulation of RANK expression 
and an increase in vascular permeability [136]. These works strengthen the role of 
RANK/RANKL axis plays in the metastatic process by regulating cancer cell migration and the 
neoangiogenesis.  
 
3.5. Immune cell regulation by RANK/RANKL: setting up fertile soil for cancer cells 
RANKL influences the microenvironment of cancer cells by acting on local immunity. The 
major role of RANKL in the immune system was initially identified in RANKL-knockout mice 
in which the development of secondary lymphoid organs was impaired, especially the lymph 
nodes [138,139], but also at the “central” level, where the maturation of the thymic epithelial 
cells necessary for T cell development was affected [140,141]. RANKL is also involved in 
modulating the immune response by inducing T cell proliferation [25] and dendritic cell 
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survival [26]. T cells activated as a result of RANKL expression stimulate dendritic cells, 
expressing RANK, to enhance their survival and thereby increase the T cell memory response 
[25]. More recently, Khan et al. demonstrated that RANKL blockade can rescue 
melanoma-specific T cells from thymic deletion, and increases the anti-tumour immune 
response as shown in melanoma [142].  
Tumour-associated macrophages (TAMs) accumulate in the tumour 
microenvironment and, depending on their M2 or M1 phenotype, play a part in tumour growth, 
angiogenesis and metastasis [143]. RANK is present at the cell membrane of 
monocytes/macrophages and RANKL acts as a chemoattractant factor for these cells [144]. The 
M2-macrophages which mainly express RANK is strongly associated with the angiogenic 
process [145]. RANK/RANKL signalling in the M2-macrophages modulates the production of 
chemokines, promoting the proliferation of Treg lymphocytes in favour of an 
immunosuppressive environment [146]. In breast carcinoma, RANKL is mainly produced by 
Treg lymphocytes (CD4+CD25+ T lymphocytes expressing Foxp3). In this context, a vicious 
cycle is established between TAMs, Treg and tumour cells resulting in tumour growth, the 
spread of cancer cells and amplification of the metastatic process [147]. In fact, T lymphocytes 
appear to be the principal source of RANKL in tumorigenesis. Whether RANKL-producing T 
lymphocytes are involved in the initial step of metastatic process or not, T lymphocytes induce 
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a permissive environment initiating the pre-metastastic niche [148].  
 
3.6. RANK/RANKL and bone niche: ongoing clinical trials  
When proliferative tumour cells are located in the bone environment (primary bone tumours or 
bone metastases), they dysregulate the balance between bone apposition and bone resorption in 
order to create a favourable microenvironment for their growth [149]. In this way, this bone 
microenvironment becomes a source of therapeutic targets, RANKL being one of them [150]. 
OPG-Fc was the first generation of drug targeting RANKL to be assessed in potsmenopausal 
women [150]. Nevertheless, due to its ability to bind to multiple ligands, and particularly to 
TRAIL [150], OPG-Fc based clinical trials have been suspended until the development of a 
monoclonal antibody targeting RANKL. Denosumab, a fully-humanised antibody targeting 
RANKL and blocking its binding to RANK, has been developed to bypass this risk [51]. In 
osteoporotic patients, Denosumab was well-tolerated and a single s.c. dose resulted in a 
prolonged decrease in bone turnover [152]. The value of blocking RANKL activities has been 
also demonstrated by the inhibition bone resorption in numerous pre-clinical models of primary 
bone tumours (Ewing sarcoma [153], osteosarcoma [154,155]), bone metastases (breast [156], 
prostate [157], non-small cell lung cancer [158]) and in myeloma [159]) and in numerous phase 
II and III clinical trials (Table 2). In breast and prostate carcinoma patients, bone turnover 
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markers were reduced in a way similar to that in the osteoporosis context and, in addition, 
delayed the onset of the first skeletal-related event and the risk of multiple SRE [160]. A 
comparison with bisphosphonate therapy demonstrated the superiority of Denosumab 
concerning the two previous parameters even if the overall survival rate was similar with both 
drugs. Additional clinical trials in metastatic diseases are currently in progress and their results 
will be very informative with regard to the clinical extension of Denosumab in oncology.  
 
4. Conclusions 
Since their initial discovery in 1997, RANK/RANKL became key actors in first bone 
remodelling and then more recently in oncology. This molecular axis is clearly involved in all 
stages of tumourigenesis, including tumour hyperplasia, pre-neoplasia foci formation, cancer 
cell migration, neo-angiogenesis, immune cell chemoattraction and the establishment of an 
immunosuppressive environment and initiation of a pre-metastatic niche. In one decade, 
RANK/RANKL has not only transformed our vision of bone biology but has also strengthened 
the notion of “seed and soil”, conventionally used to explain the metastatic process. Targeting 
RANK/RANKL signalling has already shown its therapeutic efficacy in osteoporotic patients 
and its clinical advantages in the management of bone metastases from breast and prostate 
carcinomas. Current ongoing clinical trials will be crucial for better defining its potential side 
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effects after long term use.  
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Figure legends 
Figure 1: RANK/RANKL signalling in cancer cells: a very complex molecular network. 
RANKL is a trimeric complex produced in a membrane or soluble form. Secreted RANKL can 
be produced from a specific transcript or by proteolysis of its membrane form. Trimeric 
RANKL interacts with a trimeric receptor named RANK and triggers a signalling cascade 
controlling the transcription of numerous effector genes. Additional protagonists intervene to 
regulate the binding of RANKL to RANK. In this way, OPG acts as a decoy receptor 
interacting with RANKL, and complex VIII (FVIII-vWF) showed a similar capacity. However, 
OPG is itself controlled by many ligands, including TRAIL, vWF, and glycoaminoglycans 
(GAGs), and the final inhibitory effect of OPG on RANKL is dependent on its binding to these 
ligands. Very recently, it has been demonstrated that LGR4 is a new receptor for RANKL 
which can counterbalance the RANKL activities transmitted by RANK signalling.  
 
Figure 2: RANK/RANKL is involved in each stage of cancer development: from 
pre-cancerous lesions to the establishment of metastases. Cancer cells are direct targets for 
RANKL. RANKL initiates the formation of pre-cancerous lesions by facilitating the epithelial 
mesenchymal transition (EMT) process and stemness, as well as facilitating tumour growth and 
the metastatic process by modulating immune and vascular niches. Throughout these processes, 
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RANKL acts as a chemoattractive factor for cancer cells and M2 macrophages. Activated 
macrophages facilitate both the proliferation of Treg lymphocytes, the main source of RANKL 
during primary tumour growth, and the initiation of the pre-metastatic niche in bone. RANKL 
upregulates the angiogenic process by stimulating the proliferation and survival of endothelial 
cells and, in parallel, of the metastatic process by promoting the extravasation/intravasation of 
RANK-expressing cancer cells and their migration to distant organs. The RANKL 
concentration gradient drives the tumour cells to the metastatic sites. 
 
 
 
 
 
 
 
 
Table 1: RANK and RANKL expression in cancers 
Cancer subtypes or 
related organ 
RANK expressing 
tumours 
(references) 
RANKL expressing 
tumours 
(references) 
Bladder carcinoma 51 - 
Breast carcinoma 51-56 57-60 
Cervical cancer 51, 61 61 
Chondrosarcoma 62 62, 63 
Colon and recal cancers 51 - 
Endometrial tumours 51 - 
Oesophageal tumours 51, 64 - 
Giant cell tumours of bone 65 63-66 
Hepatocarcinoma 51, 67 67, 68 
Lung cancer 51, 69 69 
Lymphoma 51, 70 71, 72 
Melanoma 73, 74 - 
Myeloma 75 75, 76 
Neuroblastoma 51  77 
Oral squamous carcinoma 78 78 
Osteosarcoma 63, 79 63, 79, 80 
Prostate carcinoma 51, 73, 82  83 
Renal carcinoma 84 84 
Thymic tumours  51 - 
Thyroid adenocarcinoma 51, 85 85 
 
Table 2: Main clinical trials based on RANKL targeting in cancers 
 
Clinical trial 
Reference 
Phase, Cancer 
type 
Title Primary outcome Patients 
enrolled 
Treatment 
(references) 
NCT01624766 I, Advanced 
malignancies 
A Phase I Trial of anakinra 
(IL-1 receptor antagonist) or 
denosumab (Anti-RANKL 
monoclonal antibody) in 
combination with everolimus 
(mTOR Inhibitor) in patients 
with advanced malignancies 
Maximum tolerated 
dose 
 
 
147 Escalating dose of denosumab  
 
Starting doses: everolimus 10 mg 
by mouth daily for a 28 day cycle. 
Denosumab 120 mg (s.c.) on Day 1 
of a 28 day cycle 
NCT01419717 III, Advanced 
cancer 
Open-label access protocol of 
denosumab for subjects with 
advanced cancer 
Subject incidence of 
treatment-emergent 
adverse events 
129 120 mg denosumab (s.c.) every 4 
weeks 
 
NCT01920568 III, Bone 
metastases 
from solid 
tumours 
A study comparing 
denosumab with zoledronic 
acid in subjects of asian 
ancestry with bone metastases 
from solid tumors 
Percent change from 
Baseline in the bone 
turnover marker  
(uNTx/uCr ) 
 
477 120 mg denosumab (s.c.) 
injection for a maximum of 13 
doses, infusion over >15 minutes 
once every 4 weeks. 
NCT02470091 II, 
Osteosarcoma 
Phase II study of denosumab, 
a RANK Ligand antibody, for 
recurrent or refractory 
osteosarcoma 
Disease control rate 
at month 4 and 12 
90 Denosumab (s.c.) on day 1 (days 1, 
8, and 15 of course 1 only). 
Treatment repeats every 4 weeks 
(28 days) for up to 24 months or 26 
courses 
NCT00396279 II, Giant cell 
tumours of 
bone 
An open-label, multi-center, 
phase 2 safety and efficacy 
Study of Denosumab (AMG 
162) in subjects with 
recurrent or unresectable 
giant cell tumor of bone 
Percentage of 
patients with tumor 
response 
 
37 120 mg denosumab (s.c.) once 
every 4 weeks, with an additional 
120 mg doses on Days 8 and 15 of 
the first month of treatmen + daily 
supplements of at least 500 mg of 
calcium and 400 IU of vitamin D 
NCT00680992 II, Giant cell 
tumours of 
An open-label, multi-center, 
phase 2 study of denosumab 
Safety profile of 
denosumab  
530 120 mg denosumab (s.c.) every 4 
weeks with a loading dose of 120 
bone in subjects with giant cell 
tumor of bone 
mg (s.c.) on study days 8 and 15 
NCT01951586 II, Non small 
cell lung 
cancer 
A randomized, double-blind, 
multi-center phase 2 trial of 
denosumab in combination 
with chemotherapy as first-
line treatment of metastatic 
non-small cell lung cancer 
Relative benefit on 
overall survival 
 
 
226 120 mg denosumab (s.c.) every 4 
weeks with a loading dose of 120 
mg (s.c.) on study days 8 and 15 
NCT02129699 III, Non small 
cell lung 
cancer 
A randomised, open-label 
phase III trial evaluating the 
addition of denosumab to 
standard first-line anticancer 
treatment in advanced 
NSCLC 
Overal survival 
 
1000 120 mg denosumab (s.c.) every 3-4 
weeks 
+ 4/6 cycles of standard 
(combination of platinum-based 
agents plus gemcitabine or 
pemetrexed) 
NCT00259740 II, Multiple 
myeloma 
An open-label, multi-center 
phase 2 trial of denosumab in 
the treatment of relapsed or 
plateau-phase multiple 
myeloma 
Complete or partial 
response based on 
M-protein 
assessments  
 
96 120 mg denosumab (s.c.) on study 
days 1, 8, 15, and 29 and every 4 
weeks thereafter 
NCT01345019 III, Multiple 
myeloma 
A randomized, double-blind, 
multicenter study of 
denosumab compared with 
zoledronic acid in the 
treatment of bone disease in 
subjects with newly 
diagnosed multiple myeloma 
Time to the first on-
study skeletal related 
event  
 
 
1700 120 mg denosumab (s.c.) every 4 
weeks 
NCT00330759 III, Multiple 
myeloma 
A randomized, double-blind, 
multicenter study of 
denosumab compared with 
zoledronic acid (Zometa) in 
the treatment of bone 
metastases in subjects with 
Time to the first on-
study skeletal-related 
event 
 
 
 
1779 120 mg denosumab (s.c.) every 4 
weeks 
 
advanced cancer (excluding 
breast and prostate cancer) or 
multiple myeloma 
NCT02099461 I, Healthy 
patients, breast  
A randomized, stratified, 
open-label, no-treatment-
controlled, parallel group, 
multicenter phase 1 trial to 
evaluate the effect of 
denosumab on cellular 
proliferation in the human 
breast 
Ratio of post-
baseline to baseline 
Ki-67 index in 
mammary epithelial 
cells 
 
82 Healthy volunteers, 60 mg 
denosumab (s .c.) on day 1 
Percutaneous core needle breast 
biopsies on day 1 (prior to study 
treatment) and day 28 
 
NCT01545648 II, Early breast 
cancer  
Pilot study to evaluate the 
impact of denosumab on 
disseminated tumor cells in 
patients with early stage 
breast cancer 
Reduction of bone 
marrow 
disseminated tumor 
cells 
 
45 120 mg denosumad (s.c.) every 4 
weeks for total of 6 months, then 
every 12 weeks for 2 doses, for a 
total treatment course of one year 
NCT01952054 II, Breast 
cancer 
Phase II study of denosumab 
to define the role of bone 
related biomarkers in breast 
cancer bone metastasis 
Reduction of 
circulating tumor 
cells  
 
35 120 mg denosumab (s.c.) every 4 
weeks (+ hormotherapy) 
NCT01864798 II, Early breast 
cancer 
A pre‐operative window 
study evaluating denosumab, 
a RANK ligand (RANKL) 
inhibitor and its biological 
effects in young 
premenopausal women 
diagnosed with early breast 
cancer 
Geometric mean 
change in tumor 
Ki67 expression 
 
 
39 Denosumab, from 30 to 120 mg 
(s.c.) once a every 4 or 12 weeks 
for 25 weeks 
NCT00091832 II, Breast 
cancer with 
bone 
metastases  
A randomized active-
controlled study of AMG 162 
in breast cancer subjects with 
bone metastasis who have not 
Percent change from 
baseline to week 13 
in creatinine-
adjusted urinary N-
255 Denosumab, from 30 to 180 mg 
(s.c.) once a every 4 or 12 weeks 
for 25 weeks 
 
previously been treated with 
bisphosphonate therapy 
telopeptide  
NCT01077154 III, Early 
breast cancer 
A randomized, double-blind, 
placebo-controlled, multi-
center phase 3 study of 
denosumab as adjuvant 
treatment for women with 
early-stage breast cancer at 
high risk of recurrence (D-
CARE) 
Bone metastasis-free 
survival 
 
4509 120 mg enosumab (s.c.) every 4 
weeks for 6 months. 120mg (s.c.) 
every 3 months for the next 4 and a 
half years.  
Supplementation: oral calcium (at 
least 500 mg) and vitamin D (at 
least 400 IU) for 5 years. 
 
NCT00321464 III, Breast 
cancer with 
bone 
metastases 
A randomized, double-blind, 
multicenter study of 
denosumab compared with 
zoledronic acid (Zometa®) in 
the treatment of bone 
metastases in subjects with 
advanced breast cancer 
Time to first on-
study skeletal related 
event 
 
2049 120 mg denosumab (s.c.) every 4 
weeks 
 
NCT00089661 III, Non-
metastatic 
breast cancer 
A randomized, double-blind, 
placebo-controlled study to 
evaluate AMG 162 in the 
treatment of bone loss in 
subjects undergoing 
aromatase inhibitor therapy 
for non-metastatic breast 
cancer 
Lumbar spine bone 
mineral density 
percent change from 
baseline at month 12 
 
 
252 Denosumab 60 mg (s.c.) every six 
months, beginning on Study day 1, 
for a total treatment period of 24 
months 
 
 
NCT02613416 II, Breast 
biomarkers 
Phase II correlative study of 
denosumab effects on tissue 
and imaging breast 
biomarkers 
(pre- and post-menopausal 
women diagnosed with stage 
0-III breast cancer) 
Safety issue 
 
44 120 mg denosumab (s.c.) per month 
 
NCT00321620 III, Prostate 
cancer with 
bone 
metastases 
A randomized, double-blind, 
multicenter study of 
denosumab compared with 
zoledronic acid (Zometa®) in 
the treatment of bone 
metastases in men with 
hormone-refractory prostate 
cancer 
Time to the first on-
study skeletal-related 
event 
 
 
1904 120 mg denosumab (s.c.) every 4 
weeks  
Zoledronic acid 4 mg (i.v.)  
 
 
NCT00286091 III, Non-
metastatic 
prostate cancer  
A randomized, double-Blind, 
placebo-controlled, multi-
center phase 3 study of 
denosumab on prolonging 
bone metastasis-free survival 
in men with hormone 
refractory prostate cancer 
Bone metastasis-free 
survival 
 
1435 Denosumab 120 mg (s.c.) every 4 
weeks  
 
NCT00089674 III, Non-
metastatic 
prostate cancer 
A Randomized, Double-
Blind, Placebo-Controlled 
Study to Evaluate AMG 162 
in the treatment of bone loss 
in subjects undergoing 
androgen-deprivation therapy 
for non-metastatic prostate 
cancer 
 
Lumbar spine bone 
mineral density 
percent change from 
baseline at month 24 
 
1468 Denosumab 60 mg (s.c.) at day 1, 
months 6, 12, 18, 24, 30 
 
NCT01824342 III, Prostate 
cancer 
An open label, single arm, 
extension study to evaluate 
the long term safety of 
denosumab for prolonging 
bone metastasis-free survival 
in men with hormone-
refractory prostate cancer 
Number of patients 
with treatment-
emergent adverse 
events and deaths 
 
18 Denosumab 120 mg (s.c.) every 4 
weeks for up to 3 years 
Source: clinical trial.gouv March 2016  
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